Breast

Tumor Mutational Burden and Response to Immune Checkpoint Therapy

(Rutgers/CINJ) Dec 14, 2017 - Predicting how patients will respond to anti-cancer therapies can be vital in informing clinical decisions and improving treatment outcome.

read press release

Daiichi Ditches Nektar Following Cancer Drug Flop

(Endpoints News) Dec 13, 2017 - Pharma giant Daiichi Sankyo is bailing on its collaboration with Nektar Therapeutics — and demanding a $12.5 million refund — following the smaller company’s failure to get its cancer drug Onzeald approved in Europe.

read article

Interdisciplinary Teams Can Help Decrease Hospital Readmissions

(CureToday.com) Dec 13, 2017 - Hospital readmissions soon after discharge can be costly and detrimental to patient care, but according to a recent study conducted at the Cleveland Clinic and presented at the 2017 American Society of Hematology’s Annual Meeting and Exposition, creating an interdisciplinary team to work with patients can help.

read article

UCLA Study Finds Link Between Breast Cancer Treatments And Cellular Markers Of Aging

(UCLA Research Alert) Dec 12, 2017 - Biological findings in breast cancer survivors who have received chemotherapy and/or radiation suggest that they may be at greater risk for accelerated aging than those who received surgery alone.

read article

Myriad’s BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP Inhibitor, Talazoparib

(Morningstar) Dec 12, 2017 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial showed Myriad’s BRACAnalysis CDx® test successfully identified patients with metastatic breast cancer (MBC) who responded to Pfizer’s investigational PARP inhibitor, talazoparib.

read article

Agendia: Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint® for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients

(Yahoo! Finance) Dec 12, 2017 - Findings of three studies presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) last week demonstrate the important role that the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test is playing in the pre-selection of patients for the I-SPY 2 trial, in achieving significant international cost savings and in adding to the limited evidence available for younger patients with breast cancer.

read article

PreludeDx Unveils Predictive Assay in DCISionRT Breast DCIS Test at SABCS

(Yahoo! Finance) Dec 13, 2017 - Prelude Corporation announced today the results from last week's oral presentation at the San Antonio Breast Cancer Symposium. The results utilizing the SweDCIS randomized trial confirmed that DCISionRT™—The DCIS Test™—predicts which patients with ductal carcinoma in situ (DCIS) will benefit from radiation therapy after breast conserving surgery.

read article

TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense

(Markets Insider) Dec 12, 2017 - TapImmune Inc., a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that the first patient has been enrolled in a Phase 2 randomized, multi-center, double-blinded, placebo-controlled clinical trial of TapImmune’s novel therapeutic vaccine candidate TPIV200.

read article

Breast Reconstruction After Cancer Less Common At Cash-Strapped Hospitals

(Reuters Health) Dec 11, 2017 - Women with breast cancer who have one or both breasts removed are less likely to get immediate reconstruction surgery at hospitals that are struggling financially, a U.S. study suggests.

read article

Use of Chemotherapy For Early Stage Breast Cancer Declines

(Stanford Medicine) Dec 11, 2017 - A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according to researchers at Stanford and the University of Michigan.

read press release

Soy, Cruciferous Vegetables Associated With Fewer Common Side Effects Of Breast Cancer Treatment

(GUMC) Dec 11, 2017 - Consuming soy foods and cruciferous vegetables may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, according to a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.

read press release

Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology

(Eli Lilly) Dec 11, 2017 - Eli Lilly and Company today announced that Kimberly Blackwell, M.D., one of the nation's leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018.

read corporate press release

A Cancer-Drug Pricing Experiment Just Got More Interesting

(BloombergGadfly) Dec 8, 2017 - The results from late-stage trial data released on Friday for Pfizer’s breast cancer drug talazoparib could push an experiment in cancer-drug price competition into overdrive.

read article

Older Women with HR-positive Breast Cancer May Receive Similar Benefit from CDK 4/6 Inhibitors as Younger Women

(2017 SABCS) Dec 8, 2017 - Older women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6) achieved progression-free survival at a rate similar to that of younger women, according to data presented at the 2017 San Antonio Breast Cancer Symposium, held Dec. 5–9.

read press release

PARP Inhibitor Improves Progression-free Survival In Patients With Advanced Breast Cancers And BRCA Mutations

(MD Anderson) Dec 8, 2017 - In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

read press release

Blood Test May Help Predict Which Breast Cancers Will Recur

(STAT/Associated Press) Dec 8, 2017 - A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

read article

Lymph Node Surgery May Raise Risk of Arm Morbidity in Younger Women

(2017 SABCS) Dec 8, 2017 - Younger breast cancer patients who underwent axillary lymph node dissection were more likely to experience arm swelling and decreased range of arm motion than patients who received sentinel lymph node biopsies, according to data presented at the 2017 San Antonio Breast Cancer Symposium, held Dec. 5–9.

read press release

Postmenopausal Women Who Lose Weight May Have Reduced Breast Cancer Risk

(2017 SABCS) Dec 8, 2017 - Postmenopausal women who lose weight may have a significantly reduced chance of developing breast cancer, according to data presented at the 2017 San Antonio Breast Cancer Symposium, held Dec. 5–9.

read press release

A Better Mammogram? Huge Study Putting 3-D Scans To The Test

(FoxNews/Associated Press) Dec 7, 2017 - A better mammogram? Increasingly women are asked if they want a 3-D mammogram instead of the regular X-ray — and now U.S. health officials are starting a huge study to tell if the newer, sometimes pricier choice really improves screening for breast cancer.

read article

Biological Factors Don't Completely Explain Racial Disparities For ‘Good Prognosis’ Breast Cancer

(UNC Lineberger) Dec 7, 2017 - Higher risk of recurrence for black women with hormone receptor-positive, HER2-negative breast cancer compared with white women cannot be completely explained by underlying biological factors, University of North Carolina Lineberger Comprehensive Cancer Center researchers reported at the 2017 San Antonio Breast Cancer Symposium on Thursday, Dec. 7.

read press release
Next Page